Press release – Biofina Diagnostics is awarded with a Seal of Excellence by the European Commission

Biofina Diagnostics S.L has been recently awarded with a Seal of Excellence by the European Commission following the presentation of its project proposal UROBEST ´UROthelial carcinoma Biomarker based diagnostic tEST´ Submitted under the Horizon 2020’s SME instrument phase 2 call H2020-SMEInst-2016-2017 (topic SMEInst-05-2016-2017) in January 16th 2017,
After being evaluated by an international panel of independent experts UROBEST was successful in a highly competitive evaluation process as an innovative project proposal. This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria: EXCELLENCE, IMPACT, QUALITY AND EFFICIENCY OF IMPLEMENTATION required to receive funding from the EU budget Horizon 2020.
The European Commission recommends this proposal for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.
Biofina Diagnostics S.L. (www.biofinadx.com) is born to further develop and take UROBEST to the market, a bladder cancer diagnostic test based on RT-qPCR technology. The company holds the exclusive exploitation and commercialization rights on Fina Biotech´s patents (www.finabiotech.es) protecting the diagnostic method. UROBEST has already been validated in clinical studies in more than 500 patients and has proven to have better sensitivity and specificity than competitive products (10-gene signature results: SN=80% and SP=94%). UROBEST® is a registered trademark in the Spanish Patent and Trademark Office (OEPM).